

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board of directors (the **“Board”**) of Shanghai Henlius Biotech, Inc. (the **“Company”**) announces that Mr. YUAN Yexing (袁擘星) (**“Mr. Yuan”**) ceased to act as the employee representative supervisor of the third session of the board of supervisors of the Company (the **“Board of Supervisors”**) due to personal development reason with effect from 31 January 2025.

Mr. Yuan has confirmed that he has no disagreement with the Board or the Board of Supervisors and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board and the Board of Supervisors expressed their gratitude to Mr. Yuan for his contribution to the development of the Company during his tenure as the employee representative supervisor of the Company.

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board is also pleased to announce that the Company convened an employee representative meeting on 31 January 2025, during which Mr. LIU Zhiyong (劉志勇) (**“Mr. Liu”**) was elected as the employee representative supervisor of the Board of Supervisors of the Company. Mr. Liu's term of office commences from 31 January 2025 until the expiry date of the third session of the Board of Supervisors.

The biographical detail of Mr. Liu is set out below:

Mr. Liu, aged 52, joined the Group in June 2020. Currently, he serves as the general manager of production. He has also served as a supervisor of the Company and a supervisor of Shanghai Henlius Biopharmaceuticals Co., Ltd.*(上海復宏漢霖生物製藥有限公司) and Shanghai Henlius Bioscience Co., Ltd.*(上海復宏瑞霖生物技術有限公司), which are the subsidiaries of the Company, since January 2025. Prior to joining the Group, Mr. Liu successively served as director of preparation workshop, manager of the planning department, and manager of the engineering department of Changchun GeneScience Pharmaceutical Limited* (長春金賽藥業股份有限公司) (currently known as Changchun GeneScience Pharmaceutical Co., Ltd.* (長春金賽藥業有限責任

公司)) from 1997 to 2012. From March 2012 to June 2017, he served as the production director at Jilin Qijian Bio-Pharmaceutical Co., Ltd.* (吉林省奇健生物技術有限公司). From July 2017 to January 2019, he served as the production director at Genovate (Changzhou) Biotechnology Co.,Ltd* (健亞(常州)生物技術有限公司). From April 2019 to May 2020, he served as assistant to the president and executive deputy general manager of Zhejiang Huajinyike Biopharmaceutical Co., Ltd.*(浙江華津依科生物製藥有限責任公司). Mr. Liu obtained a bachelor's degree in physical chemistry from Jilin University (吉林大學) in July 1997 and a master's degree in bioengineering from Jilin University in June 2016.

Mr. Liu has entered into a letter of appointment with the Company. Mr. Liu will not receive additional remuneration from the Company to act as an employee representative supervisor of the Company.

Saved as disclosed above, as at the date of this announcement, Mr. Liu has confirmed that he (i) does not hold any other positions in the Company or its subsidiaries; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship or supervisor positions in any listed companies in the past three years. As at the date of this announcement, Mr. Liu does not have any interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Saved as disclosed above, as at the date of this announcement, there is no other information in respect of Mr. Liu that needs to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there is no other matter in respect of his appointment that needs to be brought to the attention of the shareholders of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 2 February 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.

* for identification only